Asset
Apixaban
Bristol-Myers Squibb Company Common Stock
Revenue
| Period | Revenue |
|---|---|
| Q2 2026 | $4.5B |
| Q1 2026 | $4.1B |
| Q4 2025 | $3.5B |
| Q3 2025 | $3.7B |
| Q2 2025 | $3.7B |
| Q1 2025 | $3.6B |
| Q4 2024 | $3.2B |
| Q3 2024 | $3.0B |
| Q2 2024 | $3.4B |
| Q1 2024 | $3.7B |
| Q4 2023 | $2.9B |
| Q3 2023 | $2.7B |
| Q2 2023 | $3.2B |
| Q1 2023 | $3.4B |
| Q4 2022 | $2.7B |
| Q3 2022 | $2.7B |
| Q2 2022 | $3.2B |
| Q1 2022 | $3.2B |
| Q4 2021 | $2.7B |
| Q3 2021 | $2.4B |
| Q2 2021 | $2.8B |
| Q1 2021 | $2.9B |
| Q4 2020 | $2.3B |
| Q3 2020 | $2.1B |
| Q2 2020 | $2.2B |
| Q1 2020 | $2.6B |
| Q4 2019 | $2.0B |
| Q3 2019 | $1.9B |
| Q2 2019 | $2.0B |
| Q1 2019 | $1.9B |
| Q4 2018 | $1.7B |
| Q3 2018 | $1.6B |
| Q2 2018 | $1.6B |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00320255 | phase2 | completed | 2006-06-01 | 2009-01-01 | Bristol-Myers Squibb | A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer |
| NCT00496769 | phase3 | completed | 2007-08-31 | 2010-11-30 | Bristol-Myers Squibb | A Phase III Study of Apixaban in Patients With Atrial Fibrillation |
| NCT02415400 | phase4 | completed | 2015-06-04 | 2018-11-10 | Bristol-Myers Squibb | A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart |
| NCT02369653 | phase3 | completed | 2015-10-22 | 2021-07-07 | Bristol-Myers Squibb | A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase |
| NCT02981472 | phase2 | completed | 2017-01-19 | 2021-10-18 | Bristol-Myers Squibb | A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation |
FDA applications (2)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| NDA 220073 | 2025-04-17 | NDA | BRISTOL MYERS SQUIBB CO |
| NDA 202155 | 2012-12-28 | NDA | BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE |
Marketed products (7)
- ELIQUIS
- ELIQUIS
- ELIQUIS
- ELIQUIS
- ELIQUIS
- ELIQUIS
- ELIQUIS SPRINKLE